NASDAQ : IMUX
Immunic, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 7.51 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 102.47M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 100.15M |
| Enterprise Value | -54.38M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 13.64M |
| Shares Outstanding | 13.64M |
| Shares Change (YoY) | +156.51% |
| Shares Change (QoQ) | +41.07% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 52.25% |
| Float | 12.01M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.78 |
| P/TBV Ratio | 0.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.05 |
| Quick Ratio | 4.97 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -138.17% |
| Return on Assets (ROA) | -66.80% |
| Return on Invested Capital (ROIC) | -90.38% |
| Return on Capital Employed (ROCE) | -92.16% |
| Weighted Average Cost of Capital (WACC) | 12.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.12M |
| Employee Count | 100 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -5.75% |
| 50-Day Moving Average | 10.07 |
| 200-Day Moving Average | 11.50 |
| Relative Strength Index (RSI) | 38.64 |
| Average Volume (20 Days) | 366,859 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.86M |
| Short Previous Month | 2.08M |
| Short % of Shares Out | 13.64% |
| Short % of Float | 15.51% |
| Short Ratio (days to cover) | 4.11 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -117.88M |
| Pretax Income | -111.57M |
| Net Income | -111.57M |
| EBITDA | -117.73M |
| EBIT | -117.88M |
| Earnings Per Share (EPS) | -$4.00 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 155.10M |
| Total Debt | 567,000 |
| Net Cash | 154.53M |
| Net Cash Per Share | $11.33 |
| Equity (Book Value) | 127.58M |
| Book Value Per Share | 9.35 |
| Working Capital | 126.57M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -87.72M |
| Capital Expenditures | -329,000 |
| Depreciation & Amortization | 149,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -88.05M |
| FCF Per Share | -$6.45 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -156.51% |
| Shareholder Yield | -156.51% |
| Earnings Yield | -54.47% |
| FCF Yield | -87.92% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $43.09 |
| Price Target Difference | 487.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 27, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |